Codiak BioSciences (CDAK) Short Interest Ratio & Short Volume

Short interest is the volume of Codiak BioSciences shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 173,800 shares of CDAK short. Learn More on Codiak BioSciences' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CDAK shares currently have a short interest ratio of 1.0. Learn More on Codiak BioSciences's short interest ratio.

Codiak BioSciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 173,800 shares, an increase of 25.6% from the previous total of 138,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Codiak BioSciences: Bruush Oral Care Inc. (62.06%), Acorda Therapeutics, Inc. (0.66%), Scinai Immunotherapeutics Ltd. (0.29%), TC Biopharm (Holdings) Plc (30.07%), Windtree Therapeutics, Inc. (0.54%), Gamida Cell Ltd. (7.11%), Avalon GloboCare Corp. (1.74%), TRACON Pharmaceuticals, Inc. (32.67%), Finch Therapeutics Group, Inc. (1.70%), Palisade Bio, Inc. (0.21%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($3.66 billion), Occidental Petroleum Co. ($2.62 billion), Coinbase Global, Inc. ($2.38 billion), T. Rowe Price Group, Inc. ($2.13 billion), Verisk Analytics, Inc. ($2.08 billion), Snowflake Inc. ($1.95 billion), Paramount Global ($1.78 billion), Etsy, Inc. ($1.60 billion), Teck Resources Limited ($1.51 billion), and Voya Financial, Inc. ($1.49 billion). View all of the most shorted stocks.

Short selling CDAK is an investing strategy that aims to generate trading profit from Codiak BioSciences as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Codiak BioSciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CDAK, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CDAK, twice per month. The most recent reporting period available is March, 15 2023.